COSA 2015*
Chairs: Phyllis Butow & Haryana Dhillon
Fear of cancer recurrence post allogeneic hematopoietic stem cell transplant for malignant disease: Adapting to the ‘new normal’. (#166)
3:15 PM
Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)? Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). (#167)
3:20 PM
Which clinical practice guideline for cancer-related fatigue is the most suitable for application in Australia? (#168)
3:25 PM
Supportive care needs of a sample of cancer patients in metropolitan Melbourne: implications for service improvement (#169)
3:30 PM
Exercise improves quality of life, but not metabolic risk factors in men with prostate cancer undergoing androgen deprivation therapy –results of a meta-analysis. (#170)
3:35 PM